Mariana Chavez-MacGregor, MD, MSc: Clinical Rationale for Adding Everolimus to Adjuvant Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer

Posted: Thursday, December 8, 2022

Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III findings of the SWOG S1207 trial on combining adjuvant everolimus with adjuvant endocrine therapy among patients with high-risk, hormone­ receptor–positive, HER2-negative early-stage breast cancer.